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use#LAANo eﬀ  ective pharmacologic therapies currently exist for 
acute lung injury (ALI) or its more severe form, the acute 
respiratory distress syndrome (ARDS). Th  e only treat-
ment positively aﬀ  ecting mortality in ARDS is low-tidal 
volume ventilation, but even when this is used mortality 
remains high, at approximately 40% [1]. Th   us, there is an 
urgent need for eﬀ  ective therapies for ALI/ARDS. Mesen-
chymal stem cells (MSCs) are progenitor cells having 
self-renewal and multi-lineage diﬀ  erentiation capa  bilities 
along with anti-inﬂ  ammatory and immuno-suppressive 
activities. MSCs have been shown to have eﬃ   cacy  in 
various models of acute and chronic inﬂ  am  matory 
diseases [2] and are now emerging as promising cell-
based therapeutics for ALI/ARDS.
MSCs include bone marrow-derived stem cells (BMSCs), 
MSCs in umbilical cord blood, and adipose-derived stem 
cells (ASCs). In the ﬁ   eld of ALI/ARDS cell-based 
therapeutics, most attention has focused on BMSCs, 
which have therapeutic eﬃ     cacy in rodent and human 
tissue models of ALI and sepsis [3,4]. However, a number 
of barriers that may limit the clinical usefulness of 
BMSCs in human ALI/ARDS have been identiﬁ  ed [5,6] 
(Table 1). Like BMSCs, ASCs have anti-inﬂ  ammatory and 
immuno-suppressive activities. ASCs inhibit immune cell 
activation and proliferation by inducing cell-to-cell 
contact and signaling and releasing mediators that limit 
tissue injury [7]. ASCs have greater anti-inﬂ  ammatory 
potential than BMSCs because they secrete higher levels 
of bioactive mediators [8]. Th  is and other properties of 
ASCs (Table  1) make them an attractive alternative to 
BMSCs as cell-based therapeutics for human ALI/ARDS. 
Consistent with this concept, recent studies have shown 
that transplantation of autologous ASCs attenuates 
ischemia-reperfusion lung injury in rodents [9,10].
Th  e paper by Zhang and colleagues [11] builds upon 
this literature by examining whether ASCs have eﬃ   cacy 
in a model of direct ALI in mice. Zhang and coworkers 
challenged mice with bacterial lipopolysaccharide (LPS) 
by oropharyngeal route, and 4 h later ASCs isolated from 
syngeneic mice (mASCs) or humans (hASCs) were 
delivered to the mice by the same route, and ALI severity 
was assessed 24 and 72 h later. Th   e LPS-challenged  and 
mASC- or hASC-treated mice lost less body weight, and 
had decreased alveolar-capillary barrier injury as 
assessed by broncho-alveolar lavage ﬂ  uid albumin levels, 
and reduced alveolar septal thickening and exudates 
when compared with LPS-challenged mice not treated 
with ASCs. Treatment of the LPS-challenged mice with 
hASCs and mASCs also reduced polymorphonuclear 
neutro phil  inﬂ   ux into the lungs, and suppressed lung 
levels of pro-inﬂ   ammatory mediators. Murine ASCs 
increased lung levels of anti-inﬂ  ammatory interleukin-10 
in LPS-challenged mice.
A strength of the paper is its novel focus on ASCs as a 
therapy for ALI, and its approach to test ASCs thera-
peutically (rather than prophylactically) in an ALI model 
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Additionally, the authors compared the therapeutic 
eﬃ     cacy of human versus murine ASCs. While both 
hASCs and mASCs attenuated ALI, it is noteworthy that 
for most ALI parameters examined, mASCs were more 
potent than hASCs. However, it is possible that hASCs 
have greater potency at restraining acute lung 
inﬂ  ammation in human subjects.
Th   e study of Zhang and colleagues has several limita-
tions that need to be addressed before ASCs can be 
advanced to human clinical trials. First, no single ALI 
animal model can completely reproduce all the patho-
logic features of human ALI/ARDS. While the LPS model 
studied by Zhang and coworkers induces robust 
neutrophilic lung inﬂ  ammation, it causes only modest 
alveolar-capillary barrier injury, which is a hallmark of 
ALI/ARDS. Th   us, it will be important to test the eﬃ   cacy 
of ASCs in ALI models associated with severe ALI (such 
as hyperoxia and acid-induced ALI) and to assess the 
eﬀ  ects of ASCs on physiologic readouts of ALI, including 
lung compliance and hypoxemia. Second, ALI/ARDS in 
humans is often initiated by bacterial infections, but the 
model chosen (LPS-mediated ALI) causes sterile lung 
inﬂ   ammation. Given that ASCs suppress immune 
responses, it will be important to assess their eﬀ  ects on 
host responses to pathogens that can cause ALI/ARDS. 
Th  ird, the mechanisms by which ASCs produce their 
beneﬁ  cial  eﬀ   ects in this model were not addressed. 
Fourth, given that ARDS patients are often not treated 
within the ﬁ  rst 4 hours of illness (the single time-point 
when ASCs were delivered to mice in this study), future 
studies should determine how late in the disease course 
ASCs can be delivered and still induce a protective eﬀ  ect 
and for how long this protective eﬀ   ect is sustained. 
Moreover, the long-term safety of delivering ASCs was 
also not assessed in this study. It is noteworthy in this 
respect that hASCs promote the growth of tumor cells 
[12]. Th   erefore, before ASCs can be used to treat human 
subjects, it will be necessary to investigate their long-
term safety in animals.
Conclusion
Th  e study by Zhang and colleagues provides evidence 
that ASCs have potential as novel cell-based therapeutics 
for ALI/ARDS. Th   e next logical step towards advancing 
ASCs into human clinical trials for ALI/ARDS will be to 
further test ASCs for their eﬃ     cacy and safety in 
additional small and large animal models of ALI, 
including models more clinically relevant than the LPS-
mediated ALI model studied by Zhang and colleagues.
Abbreviations
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; ASC, 
adipose-derived stem cell; BMSC, bone marrow-derived stem cell; hASC, 
human adipose-derived stem cell; LPS, lipopolysaccharide; mASC, mouse 
adipose-derived stem cell; MSC, mesenchymal stem cell;
Competing interests
KG, AH, and CAO have no fi  nancial or non-fi  nancial competing interests to 
declare in relation to this manuscript.
Author’s contributions
KG, AH, and CAO all contributed to the writing of this manuscript.
Author’s information
Kushagra Gupta, MD is a post-doctoral fellow, Anja Hergrueter is a research 
technician, and Caroline Owen, MD, PhD is an Assistant Professor of Medicine 
in the Division of Pulmonary and Critical Care Medicine at Brigham and 
Women’s Hospital in Boston and Harvard Medical School. Dr Owen is also a 
fellow at the Lovelace Respiratory Research Institute, Albuquerque, NM.
Acknowledgements
This work was supported by PHS grants #HL086814 and HL111835, and 
PO1HL105339, and The Brigham and Women’s Hospital-Lovelace Respiratory 
Research Institute Consortium. These funding bodies had no role in the design 
or the writing of this manuscript or in the decision to submit the manuscript 
for publication.
Table 1. Comparison of bone marrow-derived stem cells and adipose-derived stem cells as ALI/ARDS therapeutics 
 ASCs  BMSCs
Isolation of cells Safe, relatively non-invasive and inexpensive procedure. 
Adipose tissue is abundant, expendable, easily accessible, 
and can be a waste product of many therapeutic and 
cosmetic procedures
Painful, invasive, and relatively costly procedure
Cell yields High Generally low
Proliferation and 
diff  erentiation
High proliferation kinetics; expandable in culture for 
autologous transplantation
Diff  erentiation ability impaired with increasing age
Viral infection Adipose tissue does not have high exposure to viruses Bone marrow cells are susceptible to virus infection 
and replication, including hepatitis B and human 
immunodefi  ciency virus
Effi   cacy Few reports of effi   cacy in lung injury models to date; not yet 
tested in sepsis models
Effi   cacy demonstrated in animal models of ALI and sepsis
Other ASCs promote the growth of tumor cells 
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; ASC, adipose-derived stem cell; BMSC, bone marrow-derived stem cell.
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